Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.57 |
| ▸ | TDO2 | P48775 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CDC42 | P60953 | 2/20 | 0.44 |
| ▸ | RAC1 | P63000 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8154614 | 0.87 | IDO1 (0.55) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL5752075 | 0.84 | POLB (0.48) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL30638066 | 0.83 | MAPT (0.55) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL3829305 | 0.83 | MAPT (0.55) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL3019686 | 0.83 | NCEH1 (0.58) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL5752998 | 0.81 | POLB (0.55) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL5478495 | 0.80 | LMNA (0.45) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL8395861 | 0.80 | POLB (0.50) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL3160115 | 0.80 | POLB (0.50) | IDO1TDO2POLBRXFP1LMNA | |
| SCHEMBL13781592 | 0.80 | NCEH1 (0.60) | IDO1TDO2POLBRXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1073640-B1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000008495-A2 | ANTIPROLIFERATIVE NAPHTHOQUINONES, DERIVATIVES, COMPOSITIONS, AND USES THEREOF | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | IDO1 1675/4885TDO2 414/4885POLB 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.